NCIt definition : A long-acting formulation consisting of an engineered and mutated form of the endogenous
cytokine interleukin-2 (IL-2; IL2) fused with human recombinant albumin, with minimal
to no binding affinity for IL-2 receptor subunit alpha (IL-2Ralpha; CD25) and with
high binding affinity for the beta receptor subunit (IL-2Rbeta; IL2Rb; CD122), with
potential immunostimulating and antineoplastic activities. Upon administration, IL-2
superkine-recombinant human albumin fusion protein MDNA11 primarily targets and preferentially
binds to CD122. The binding of IL-2 to CD122 activates IL2Rb-mediated signaling in
immune cells, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK)
cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma
(IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-
and NK-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction.
The fusion of IL-2 with human recombinant albumin allows for longer half-life and
enables accumulation at the tumor site.. As MDNA11 does not bind to CD25 expressed
on regulatory T-cells (Tregs), the IL-2-mediated activation of Tregs and Treg-mediated
immunosuppression is halted.;